PTAB Denies Novartis' Challenge To Cancer Drug Patents
Law360 (January 18, 2019, 7:36 PM EST) -- The Patent Trial and Appeal Board has declined to review two Plexxikon Inc. patents related to a skin cancer treatment, dealing a setback to Novartis Pharmaceuticals Corp., which is facing infringement allegations over a rival medication.
The PTAB, in decisions Wednesday, denied separate requests from Novartis to examine the patents in America Invents Act reviews. In one case, the PTAB said Novartis made arguments that had already been considered by an examiner during prosecution.
“We recognize that petitioner has a direct interest in pursuing the instant petition, but we also recognize the burden and expense to patent owner in having to...
Stay ahead of the curve
In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.
Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
Create custom alerts for specific article and case topics and so much more!